BrainMap

Valentina Anuta

PhD

Associate Professor - UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA"

Researcher | Teaching staff | Scientific reviewer

Web of Science ResearcherID: F-4819-2011

Curriculum Vitae (26/02/2024)

Expertise & keywords

Development of anticancer nanoparticulate systems based on novel metal complexes Call name: P 2 - SP 2.1 - Proiect experimental - demonstrativ
PN-III-P2-2.1-PED-2019-5143 2020 - 2022

Role in this project: Key expert

Coordinating institution: INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU"

Project partners: INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU" (RO); UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (RO)

Affiliation: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (RO)

Project website: https://www.virology.ro/ro/cercetare/proiecte/proiect-ped-383-2020

Abstract:

A new generation of efficient metal-based drugs needs to be developed in order to overcome the biological, biopharmaceutical and biomedical drawbacks of standard chemotherapy. Use of metallo-drugs in cancer treatment has been hampered by an indaquate pharmacokinetic profile that limited the access to the biological target. This has led to the development of novel technologies based on nanostructured materials, acting as vectors for metallodrug delivery or simply as protectors of active species of the complexes for amplifying their activities and reducing their degradation. The aim of the project is to develop and validate new liposomal systems for transport and delivery of 2 promising anticancer agents previously studied by our research group. Nanoparticulate drug carrier systems will improve the therapeutic effectiveness and safety profile of these novel anticancer agents. The efficiency of these nanoformulations will be evaluated in terms of stability, drug entrapment efficiency, release behaviour, cell uptake, cytotoxicity, farmacotoxicology and pharmacokinetics. The project specific objectives are: 1) Development of liposomal systems validated at the laboratory level with novel anticancer agents; 2) Estimation the in vitro biological activity of the liposomal systems on various cell lines, including drug resistant cell lines, identifying biomarkers involved in modulating their biological activity; 3) Estimating the pharmaco-toxicological and pharmacokinetic profile of liposomal systems. Nanoparticles provide an enhanced bioavailability, in vivo stability, intestinal permeability, solubility, sustained and targeted delivery, therapeutic effectiveness of the anticancer drugs. The proposed project is a complex, interdisciplinary study related to biomedical international research, that aims to intends to transform modern methods, worldwide used in pharmacological, immunological and molecular biology studies, in instruments used for the translation to oncology.

Development of smart and low energy input processing chains, natural food additives and colourants, and supportive material for a code of practice to increase sustainability and consumer acceptance of organic food stuffs Call name: P 3 - SP 3.2 - Proiecte ERA.NET
ERANET-COREORGANIC-SusOrgPlus 2018 - 2021

Role in this project:

Coordinating institution: UNIVERSITATEA DE STIINTE AGRONOMICE SI MEDICINA VETERINARA

Project partners: UNIVERSITATEA DE STIINTE AGRONOMICE SI MEDICINA VETERINARA (RO)

Affiliation: UNIVERSITATEA DE STIINTE AGRONOMICE SI MEDICINA VETERINARA (RO)

Project website: https://www.usamv.ro/index.php/ro/696-susorgplus

Abstract:

Organic food processing is characterised by empirical approaches resulting in high specific raw material and energy demands as well as product deterioration, thus, impacting on overall sustainability and product quality. Steps towards mitigation have been taken (Core Organic Plus), but there is still a lack of a clear Code of Practice.

Restrictions in the usage of additives and the need of phasing out contentious materials further increase pressure whilst the full potential of natural additives and colourants is not explored. SusOrgPlus will address these issues for the processing and production of value added products of selected plant and animal origin products through the development of novel, smart processes, natural additives/colourants and supporting material for a Code of Practice. Inclusion of leading food scientists, process, mechanical and control engineers, agriculturalist and a technology provider and utilisation of a stakeholder guided approach will assure all aspects relevant for the development of smart, efficient and low energy input processes and value added products. The geographical balance, with participants from Central, Eastern, Northern and Southern Europe, will assure the relevance of the project across the EU and beyond.

USAMV Bucharest's contribution to the objectives of the SusOrgPlus project will provide to the ecological sector: (a) value-added products (natural additives/colourants); (b) increasing the processing technology efficiency, reducing specific consumption of bio-resources; (c) reduction of direct waste resulting from the processing of fresh raw material; (d) quality and sensory assessment of the innovative organic products obtained; (f) analyzing the acceptability of consumers for organic food enriched with food additives and natural dyes; (g) supportive material for a code of practice; (h) dissemination of project results and training of farmers/processors, other stakeholders involved in education and research (students, master students, PhD students, teachers, researchers, etc.).

The development of an innovative gel based on herbal extracts for the treatment of haemorrhoidal diseases Call name: P 2 - SP 2.1 - Cecuri de inovare
PN-III-P2-2.1-CI-2018-1124 2018 - 2018

Role in this project:

Coordinating institution: HOFIGAL EXPORT IMPORT SA

Project partners: HOFIGAL EXPORT IMPORT SA (RO); UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (RO)

Affiliation: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (RO)

Project website: https://umfcd.ro/cercetare-si-dezvoltare/proiecte/proiecte-nationale/proiect-pn-iii-p2-grant-2-1-ci-2018-1124-nr-191ci-2018-dezvoltarea-unui-gel-inovativ-pe-baza-de-extracte-vegetale-cu-aplicabilitate-in-terapia-afectiunilor-hemoroidale/

Abstract:

The project aim is the obtaining a new gel-like pharmaceutical product from plant extracts and demonstrating its efficacy through laboratory animal tests for introduction into hemorrhoid therapy. The collaboration with the University partner will lead to the production of plant extracts, physicochemical characterization and standardization using botanical, analytical and pharmacognostical methods, efficacy and safety assessment by pharmacological and toxicological methods on laboratory animals and pharmaceutical formulation and testing of the pharmaceutical parameters of the preparation. The innovative feature of the project will ensure the patenting of the anti-hemorrhoidal gel and its introduction into manufacturing for marketing purposes. The expected results are described by the economic impact after implementing the project, increasing the company's portfolio with a new product with scientifically proven therapeutic efficacy and increasing the company's competitiveness.

OPTIMIZATION OF THE MODERN TECHNOLOGY FOR PROCESSING BREWING SPENT YEAST AND OBTAINING OF DERIVED PRODUCTS Call name: P 2 - SP 2.1 - Transfer de cunoaștere la agentul economic „Bridge Grant”
PN-III-P2-2.1-BG-2016-0308 2016 - 2018

Role in this project:

Coordinating institution: UNIVERSITATEA DE STIINTE AGRONOMICE SI MEDICINA VETERINARA

Project partners: UNIVERSITATEA DE STIINTE AGRONOMICE SI MEDICINA VETERINARA (RO); INSTITUTUL NATIONAL DE CERCETARE-DEZVOLTARE PENTRU TEXTILE SI PIELARIE - INCDTP BUCURESTI (RO); UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO); PHARMACORP INNOVATION S.R.L. (RO); UNIVERSITATEA POLITEHNICA DIN BUCURESTI (RO); AGSIRA SRL (RO)

Affiliation: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO)

Project website: http://www.usamv.ro/dgpcsa-cdi/optimizarea-tehnologiei-moderne-de-procesare-drojdiei-uzate-de-bere-si-de-obtinere-produselor-derivate-biodryyeast/

Abstract:

The consortium consists of five research organizations that aim to obtain new products through optimization and validation of technologies, as well as to provide recommendation for the modernization of the existing production lines. The main objective of the industrial producer AGSIRA is to provide at least one new product to existing customers.

The research organizations will tackle together with AGSIRA the following issues established based on the needs identified at the industrial producer:

-design of a new production line to produce brewing yeast as feed through a new biotechnological process;

-obtaining a new product, having superior quality in comparison with the existing product in terms of composition, by optimizing the mixture between the yeast produced by the new technology with current processed spent brewing yeast;

-obtaining active brewing yeast (by freeze-drying and atomization);

-obtaining of derived products based on brewing yeast.

DESIGN, EVALUATION AND MODELING OF DRUG RELEASE MECHANISM FOR NOVEL TOPICAL MULTIPARTICULATE DELIVERY SYSTEMS Call name: P 2 - SP 2.1 - Proiect experimental - demonstrativ
PN-III-P2-2.1-PED-2016-0813 2017 - 2018

Role in this project:

Coordinating institution: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA

Project partners: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO); INSTITUTUL NATIONAL DE CERCETARE-DEZVOLTARE PENTRU TEXTILE SI PIELARIE - INCDTP BUCURESTI (RO)

Affiliation: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO)

Project website: https://umfcd.ro/cercetare-si-dezvoltare/proiecte/proiecte-nationale/proectarea-evaluarea-si-modelarea-mecanismului-de-eliberare-a-medicamentului-pentru-noi-sisteme-multiparticulate-de-cedare-topica/

Abstract:

TOPMULTINOV project is a new and modern concept for the development of smart biomaterial supports usable in burned skin repair. Efficient regeneration of burned skin is still a clinical challenge, obtaining of an adequate drug release support being a top approach in the field of biomaterials. The general objective of this project consists of the design, evaluation and modeling of an anti-inflammatory drug release mechanism from topical multiparticulate systems that will ensure a controlled release for burns healing. As a novelty element of the project, ensuring a proper anti-inflammatory drug delivery from spongious collagen-based supports using different techniques that allow a gradual degradation of collagen support and a slow release of drug is mentioned. The vehicle formulation in the drug delivery sciences is a critical quality attribute which needs special attention for tailor made design to rationalize the system development. Thus, the project presents a new approach concerning the preparation of release supports like collagen-based spongious matrices with an anti-inflammatory drug incorporated in free form, in free and encapsulated form, and in encapsulated form respectively, to model and control its release rate. The results generated by the preparation, physico-chemical and morphological characterization as well as the in vitro studies of drug release and testing of the designed topical systems on animal model will be disseminated at conferences, in specialty articles, and by patent application. The pluridisciplinarity and complementarity of both teams provide high level of scientific/technical experiences to ensure a successful project achievement. TOPMULTINOV is perfectly integrated in the national and European strategies with respect to the impact on human health for improved health and life quality.

Self-emulsifying delivery system for new metal complexes as materials with potential health use Call name:
15BM/2016 2016 - 2017

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA"

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (RO)

Affiliation: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (RO)

Project website:

Abstract:

INNOVATIVE THERAPEUTIC PRODUCTS WITH PROPHILACTIC AND CURATIVE ACTION FOR ZOO-VETERINARY SECTOR Call name: Joint Applied Research Projects - PCCA 2013 - call
PN-II-PT-PCCA-2013-4-0953 2014 - 2017

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA DE STIINTE AGRONOMICE SI MEDICINA VETERINARA

Project partners: UNIVERSITATEA DE STIINTE AGRONOMICE SI MEDICINA VETERINARA (RO); UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO); ASOCIATIA CENTRU DE CERCETARE STIINTIFICA IN DOMENIUL BIOCHIMIEI APLICATE SI BIOTEHNOLOGIEI (BIOTEHNOL) (RO); BIOING S.A. (RO); HOFIGAL EXPORT IMPORT SA (RO)

Affiliation: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO)

Project website: http://sanovet.fifim.ro/

Abstract:

Title: „INNOVATIVE THERAPEUTIC PRODUCTS WITH PROPHILACTIC AND CURATIVE ACTION FOR ZOO-VETERINARY SECTOR”

Acronym: SANOVET

Program: PARTNERSHIPS

Subprogram: “ Applied Collaborative Research Projects”

Domain 5 - Agriculture, food safety and security

Research thematic: 5.1.4. Methods, techniques and technologies for growth and diversification of animal production and fisheries, veterinary protection insurance Animal health is a concern for all European citizens. This concern stems from the public health, food safety and food security aspects, which are related to animal health but also to economic costs that animal disease outbreaks can trigger. This project uses a very common and a high economical and ecologically impact disease model like inflammation, as a paradigm for a conceptual and practical approach aimed to capitalize inexpensive and available resources.

The project goal is to improve the level of veterinary protection by developing a semi - solid phytoproduct from indigenous flora with topical application.

Main objectives that will ensure the achievement of project aim are:

1. Obtaining crops to exploit the curative potential of Anthriscus sp.;

2. Obtaining the phytocomplex;

3. Evaluating extracts pharmacological viability;

4. Obtaining an innovative phytoproduct .

The results of this research project will be materialized through:

1. Development and characterization of a herbal extract enriched in active ingredients with a complex chemical structure, non-toxic, based on original recipe obtained from association of fractionated extract with volatile oil from Anethum sp properly processed,

2. Highlighting the biologic activity, which plays a role in sustaining and accelerating the healing process by in vivo testing of herbal extract,

3. Creating a new topic semisolid phytoproduct.

The project addresses to a major agricultural problem in an interdisciplinary aggregate approach in order to achieve high yields results with a low economical input and a great environmental safety.

RESEARCH AND FORMULATION OF A NEW CLASS OF SYNERGIC ANALGESIC - ANTIINFLAMMATORY DRUG COMBINATIONS WITH IMPROVED BIOAVAILABILTY, EFFICACY AND SAFETY PROFILE Call name: Joint Applied Research Projects - PCCA 2013 - call
PN-II-PT-PCCA-2013-4-2071 2014 - 2017

Role in this project: Key expert

Coordinating institution: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA

Project partners: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO); Spitalul Universitar de Urgenta Militar Central "Dr.Carol Davila" (RO); UNIVERSITATEA DE MEDICINA SI FARMACIE CRAIOVA (RO); UNIVERSITATEA BUCURESTI (RO); POLIPHARMA INDUSTRIES S.R.L. (RO)

Affiliation: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO)

Project website: http://www.algosyn.org

Abstract:

The project aims a “faster medicine” (an European priority), an unitary, optimal, complete approach, from pharmacological design to clinical trial and industrial development of synergic combinations of an analgesic (acetaminophen), an analgesic - anti-inflammatory (acetylsalicylic acid), caffeine and chlorphenamine or other antihistaminic, exhibiting analgesic, anti-inflammatory and decongestive action, formulated as tablets, enterosoluble dragees, capsules.

The technical problem proposed to be solved in the project is that of obtaining the anti-inflammatory, analgesic and decongestant effects in pain related to inflammatory processes, particularly those in migraine, lumbar discopathy and/or lumbago, when smaller than regular quantities of active substances are administered, with relative higher efficiency than the substances administered individually and with reduced side effects and higher patient tolerance.

Additional to superior effects in comparison with the individual components, the essential , original feature of the new products will be that of obtaining comparable effects as other similar drug combinations but at two-three times lower doses, which implies also a significant reduction of adverse events. Particularly, the administration of acetylsalicylic acid as a nanostructured formulation diminishes high local concentrations of dissolved drug in the gastro-intestinal tract which is expected to minimize gastro-intestinal irritancy.

Research looks for a class of new combinations having as leading drug a synergic combination between chlorphenamine, caffeine, acetaminophen and acetylsalycilic acid, existing in the weight ratios of 1/10/30/40) patented by the project director and finalized as a drug, Algopirin, authorized by National Medicines Agency and produced by the industrial partner of the project. The most remarkable result was a strong anti-migraine effect.

The originality of the project lies also in the methodology and phenomenological modelling. The methodological approach will be based on powerful design of experiments, mainly cross-over, mathematical modelling and statistical tools. This could offer a chance of understanding the variability mechanisms and time-course of the processes which will allow to obtain statistical and clinical significant results, starting from a minimum number of experimental and clinical trials.

Pharmaco/ Toxico/ Kinetics and Dynamics modelling would have as result the elaboration of general and personalized therapeutic schedules for new drugs, prevention of non- responsiveness appearance following an inappropriate pharmacokinetics. Design, elaboration and characterization of classical and/or supramolecular organic core-shell nano-silica reservoirs, for release of active components, will be the contribution in the project of the colloid chemistry partner team and the industrial partner of the project. Nanostructured formulations will provide improved dissolution rate of active components that would result in enhanced bioavailability allowing a smaller dose to achieve same in vivo blood levels.

The most significant feature of the project is the aim of finalizing the researches with new, in the same time more safe and efficient drugs.

Design and development of transport and delivery systems for new ruthenium compunds with antitumor activity Call name: Joint Applied Research Projects - PCCA-2011 call, Type 2
PN-II-PT-PCCA-2011-3.2-1454 2012 - 2016

Role in this project:

Coordinating institution: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA

Project partners: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO); INSTITUTUL ONCOLOGIC PROF.DR.ALEXANDRU TRESTIOREANU BUCURESTI (RO); UNIVERSITATEA BUCURESTI (RO); INSTITUTUL DE VIRUSOLOGIE "STEFAN S.NICOLAU" (RO); PHARMA SERV INTERNATIONAL SRL (RO)

Affiliation: UNIV.DE MEDICINA SI FARMACIE - CAROL DAVILA (RO)

Project website: http://cercetare-umf.ro/uploads_ro/592/Pagina_web_136_2012-actualizata_2016.pdf

Abstract:

The proposed cooperative study is a complex interdisciplinary approach aimed at developing pharmaceutical product models with significant antitumor action and minimal side effects. During the project, three pharmaceutical systems that include some ruthenium complexes will be studied regarding solubility, capacity to transport and deliver the active substance at the final site of action, the antitumor activity and the side effects. The final scope of the project is to select the system (or systems) who best meet the requirements regarding bioavailability and pharmaco-toxicological properties for a possible inclusion in the clinical trials of the studied ruthenium complexes.

The proposed project has least three main goals. First, we want to develop pharmaceutical systems for improve the solubility of some ruthenium compounds in order to achieve a better pharmacokinetic profile for these compounds. Second, we intend to evaluate the antitumor activity of the developed systems using various cell lines from solid tumors and in vivo, comparing to cisplatin as reference substance. Third, we intend to evaluate the general toxicity of the developed systems, comparing to cisplatin. Additionally, we want to explore the possibility of development of these products as oral drugs and to establish what kind of cancer can be treated with these agents.

In silico, in vitro and ex vivo research concerning anti-infective compounds Call name:
2011 - 2013

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA"

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (RO)

Affiliation: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (RO)

Project website:

Abstract:

Synthesis, characterization and testing of biological activity of some new ruthenium complexes, potential alternative to platinum therapy Call name:
PNII 61-048/2007 2007 - 2010

Role in this project: Key expert

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA"

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" ()

Affiliation: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" ()

Project website:

Abstract:

Transformarea Universității de Medicină și Farmacie „Carol Davila” din București într-un Hub de incluziune pentru studenții cu dizabilități Call name: Fondul de Dezvoltare Instituţională - FDI - Competiţia 2024
CNFIS-FDI-2024-F-0567 2024 -

Role in this project:

Coordinating institution: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA"

Project partners: UNIVERSITATEA DE MEDICINA SI FARMACIE "CAROL DAVILA" (RO)

Affiliation:

Project website:

Abstract:

FILE DESCRIPTION	DOCUMENT
List of research grants as project coordinator
List of research grants as partner team leader
List of research grants as project coordinator or partner team leader
Significant R&D projects for enterprises, as project manager
R&D activities in enterprises
Peer-review activity for international programs/projects